TRVI - Company ID 0001563880
Trevi Therapeutics, Inc. trades as TRVI and has a market capitalization of $2.65 B, making it the #1940 largest US-listed company by market value. This page tracks Trevi Therapeutics, Inc. through 524 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13D/A | - | 2026-05-07 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| Proxy statement | DEF 14A | 2026-04-21 |
| Annual report to shareholders | ARS | 2026-04-21 |
| Proxy materials | DEFA14A | 2026-04-21 |
| Prospectus supplement | 424B5 | 2026-04-17 |
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO
T he Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough
Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025
The largest companies sharing Trevi Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Trevi Therapeutics, Inc. (TRVI) has a market capitalization of $2.65 B as of 2026-07-09, ranking #1940 among US-listed companies.
In its latest fiscal year Trevi Therapeutics, Inc. reported a net loss of $42.76M.